Medera’s Successful Heart Trial Enrollment Now Complete
No gene therapy–related serious adverse events have been reported to date across both cohorts in Medera’s Phase 1/2a MUSIC-HFpEF...
eClinical Tech News
Study Finds Babesia Infection in 24% of Chronic Fatigue Cases
Babesia DNA was detected in 24% of a 50‑patient cohort with at least six months of fatigue and concurrent...
Theriva Gets Positive EMA Advice for VCN-01 Phase 3 Trial
Theriva’s Phase 2b VIRAGE trial in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) reported improvements in overall survival, progression-free survival,...
Breakthrough Trial Offers New Hope for Stargardt Disease
Tinlarebant reduced the growth rate of Stargardt lesions by 35.7% versus placebo over 24 months in the Phase 3...
New Data: Leqembi’s Expanding Benefit for Early Alzheimer’s
Modeled long-term analyses from the Clarity AD open-label extension estimated that continuous lecanemab could delay progression from mild cognitive...
New Hope in NSCLC: Enozertinib’s Powerful CNS Activity
Topline data from ORIC’s Phase 1b study of enozertinib (ORIC-114) in EGFR exon 20–mutated NSCLC show a 67% best...
Apeiron Presents First-in-Human Data for GTA182 in NSCLC
Topline readout: In an ongoing Phase 1 study of GTA182 in MTAP-deleted solid tumors, the objective response rate was...
Bioversys Launches Promising Phase 3 Trial for BV100 Drug
In a Phase 2 study in ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii, BV100 delivered a 50% relative...
Study Assesses Emrosi™ (DFD-29) Impact on Microbial Flora
In a 60-subject, randomized, double-blind, placebo-controlled Phase 1 study, 16 weeks of low-dose oral minocycline (Emrosi, 40 mg modified-release;...
Atumelnant Pivotal Trial for Adult CAH Doses First Patient
Phase 2 data for atumelnant in adults with classic congenital adrenal hyperplasia (CAH) showed rapid, substantial and sustained reductions...